Showing results (121-130 of 229) with videos related to
Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2005
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancerH J Huang, P Neven, M Drijkoningen, et al.Facts, Views & Vision in Obgyn|July 5, 2022
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinionI Vergote, H Denys, S Altintas, et al.Journal of Clinical Pathology|May 27, 2005
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancerH J Huang, P Neven, M Drijkoningen, et al.Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|April 21, 2007
Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methodsB Van Calster, D Timmerman, C Lu, et al.Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|October 16, 2012
Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studiesJ Kaijser, T Bourne, L Valentin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentA Howell, J F R Robertson, J Quaresma Albano, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapyM J Piccart, A Floquet, G Scarfone, et al.Gynecologic Oncology|August 31, 2013
PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancerH Dauwen, B Van Calster, C M Deroose, et al.Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|July 6, 2013
Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?J Kaijser, T Van Gorp, M-E Smet, et al.Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.Pageof 23